Page last updated: 2024-08-24

imiquimod and plx 4720

imiquimod has been researched along with plx 4720 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bellmann, L; Brinckerhoff, CE; Cappellano, G; Mullins, DW; Ortner, D; Prokopi, A; Schachtl-Riess, JF; Seretis, A; Stoitzner, P; Tripp, CH	1

Other Studies

1 other study(ies) available for imiquimod and plx 4720

Article	Year
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. International journal of cancer, 2020, 03-01, Volume: 146, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imiquimod; Indoles; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mutation; Natural Killer T-Cells; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; T-Lymphocytes; Toll-Like Receptor 7	2020

Article

Year

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.

International journal of cancer, 2020, 03-01, Volume: 146, Issue:5

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imiquimod; Indoles; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mutation; Natural Killer T-Cells; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; T-Lymphocytes; Toll-Like Receptor 7

2020